Clinical bottom line
Immune repertoire sequencing (IRS) offers a promising approach to characterize the diversity and clonality of B and T cell receptors in autoimmune diseases. Early evidence suggests IRS may help identify disease-specific immune signatures, monitor treatment response, and potentially guide personalized therapy selection. However, its clinical utility remains investigational, with limited prospective data validating its predictive value or impact on patient outcomes. Clinicians should consider IRS as a research tool currently, with cautious interpretation until further validation in well-designed clinical studies.
What the evidence shows
Immune repertoire sequencing leverages high-throughput sequencing technologies to profile the variable regions of T cell receptors (TCRs) and B cell receptors (BCRs), providing detailed insights into adaptive immune responses. This approach can detect clonal expansions, track autoreactive clones, and reveal immune dysregulation patterns relevant to autoimmune pathogenesis (Hu et al., 2024; National Cancer Institute et al., 2020).
Hu et al. (2024) provide a comprehensive review highlighting IRS’s diagnostic, therapeutic, and prognostic potential across multiple autoimmune diseases. They describe how distinct TCR/BCR repertoires correlate with disease activity and phenotype in conditions such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. IRS has shown promise in identifying autoreactive clones that may serve as biomarkers for disease onset or flare prediction. Moreover, longitudinal repertoire analysis may detect early immune changes preceding clinical relapse, potentially enabling preemptive therapeutic adjustments.
IRS also holds potential for guiding personalized therapy by revealing dominant pathogenic clones or immune pathways amenable to targeted intervention. For example, repertoire shifts after B cell depletion or T cell–targeted therapies may inform treatment efficacy and durability. However, the clinical translation of these findings is nascent, with most data derived from small cohorts or cross-sectional studies.
The National Cancer Institute et al. (2020) provide definitions and technical considerations for IRS, emphasizing the need for standardized protocols and bioinformatics pipelines to ensure reproducibility and comparability across studies. They note that IRS can complement traditional immunophenotyping and serologic assays but requires integration with clinical context.
Earlier work on TCR revision and repertoire changes in autoimmune diseases (Jia et al., 2018) was withdrawn, underscoring the evolving and sometimes uncertain nature of this research field.
Caveats and uncertainty
Despite its promise, IRS faces several limitations that currently restrict its routine clinical application. First, the complexity of immune repertoires and interindividual variability complicate the identification of disease-specific signatures. Many autoimmune diseases exhibit heterogeneous immune profiles, and distinguishing pathogenic clones from benign expansions remains challenging.
Second, there is a lack of large-scale prospective studies demonstrating that IRS-guided interventions improve clinical outcomes. Most evidence is hypothesis-generating or derived from retrospective analyses, limiting conclusions about causality or utility in treatment decision-making.
Third, technical variability in sample processing, sequencing platforms, and data analysis pipelines can affect results. Standardization efforts are ongoing but not yet universally adopted, which may hinder cross-study comparisons and clinical implementation.
Fourth, the cost and turnaround time of IRS remain barriers for widespread use, particularly in routine clinical settings.
Finally, ethical and privacy considerations related to deep immune profiling warrant careful attention, especially when integrating IRS data with other genomic information.
How this may change practice
If validated in prospective clinical trials, immune repertoire sequencing could become a valuable tool for precision immunology in autoimmune diseases. Potential applications include:
- Early diagnosis and risk stratification by detecting disease-specific autoreactive clones before clinical manifestations.
- Monitoring disease activity and predicting flares through dynamic repertoire changes.
- Personalizing therapy by identifying dominant pathogenic clones or immune pathways to target, optimizing treatment choice and dosing.
- Assessing treatment response and guiding tapering or escalation strategies based on immune repertoire remodeling.
In the near term, IRS is best utilized within research protocols or specialized centers with expertise in immunogenomics. Clinicians should remain informed about emerging data but interpret IRS results cautiously until robust clinical validation is available.
Integration of IRS with other biomarkers, clinical parameters, and imaging may enhance its predictive power and clinical relevance. Collaborative efforts to standardize methodologies and share data will be critical to advancing IRS toward routine clinical use.